I tend to agree. Efti has vast potentials outside/beside...

I tend to agree. Efti has vast potentials outside/beside oncology but my big bet is on IMP761.

January last year I wrote to the company and emphacise focussing taking MP761 off the ground and highlighting its importance as a merging therapeautic drug in a very competative immunotherapy landscape. I was pleased to have Marc take time to reply to my email quite in length (of course without providing material information), essentially acknowledging the fact and saying IMM was putting more effort into IMP761, again without providing details. I was delighted to later last year (almost exactly a year ago) they moved IMP761 and partnered with Charles River. So, all in all i am plessed with where we are, despite up and fowns, and there may well be more downs in future too but thats the nature of the game. In the universal scheme of things it is all worth it.